BUZZ-Trillium Therapeutics Inc: Oppenheimer starts with "outperform" rating

Fri May 15, 2015 9:17am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canada-based drugmaker's shares up 11 pct at $20.60 premarket

** Oppenheimer & Co starts coverage with "outperform" rating and price target of $32

** Company could start testing its lead therapy, SIRPFc, in indications other than blood cancer in the next 12-18 months, analyst Christopher Marai writes in a note

** Marai says each of the upcoming trials could yield profound results

** Up to Thursday's close, the stock had more than doubled this year